Tetsuya Ikemoto1,2, Mitsuo Shimada3, Daichi Ishikawa3,2, Yoichiro Kawashita3, Hiroki Teraoku3, Masato Yoshikawa3,2, Shinichiro Yamada3, Y U Saito3, Yuji Morine3, Satoru Imura4. 1. Department of Digestive and Transplant Surgery, Institute of Health Bioscience, Graduate School of Medicine, University of Tokushima, Tokushima, Japan ikemoto.tetsuya@tokushima-u.ac.jp. 2. Fujii Memorial Institute of Medical Sciences, University of Tokushima, Tokushima, Japan. 3. Department of Digestive and Transplant Surgery, Institute of Health Bioscience, Graduate School of Medicine, University of Tokushima, Tokushima, Japan. 4. Department of Minimum Invasive and Telesurgery, Tokushima University Hospital, Tokushima, Japan.
Abstract
BACKGROUND/AIM: Recently CD4+CD49b+ LAG3+regulatory T (Tr1) cells are reported to be IL-10 driven, have strong regulatory activities. Thus, this study aimed to investigate whether Treg and Tr1 cells participate in immunological status against cancer. PATIENTS AND METHODS: Peripheral blood was withdrawn from patients (n=78), and healthy volunteers as controls (n=23). The peripheral blood mononuclear cells were subjected to FACScan analysis after labeling with anti-CD4, -CD25, - Foxp3, -CD49b and -LAG3 antibodies. Resected specimens were stained for IL-10. Patients' clinical course and clinicopathological factors were compared. RESULTS: Tr1 was significantly higher in patients with cancer (p=0.02). Among patients who underwent R0 resection, those with early recurrence had a significantly higher pre-/post-operative Tr1 ratio (p<0.05). Median pre-/post-operative ratios of Foxp3Tregs and Tr1s predicted early recurrence with 85.6% sensitivity and 93.3% specificity. Disease-free survival was significantly lower in patients with high IL-10 expression in resected specimens. CONCLUSION: Peripheral Tregs and Tr1 indicate immunological state against cancer. Copyright
BACKGROUND/AIM: Recently CD4+CD49b+ LAG3+regulatory T (Tr1) cells are reported to be IL-10 driven, have strong regulatory activities. Thus, this study aimed to investigate whether Treg and Tr1 cells participate in immunological status against cancer. PATIENTS AND METHODS: Peripheral blood was withdrawn from patients (n=78), and healthy volunteers as controls (n=23). The peripheral blood mononuclear cells were subjected to FACScan analysis after labeling with anti-CD4, -CD25, - Foxp3, -CD49b and -LAG3 antibodies. Resected specimens were stained for IL-10. Patients' clinical course and clinicopathological factors were compared. RESULTS:Tr1 was significantly higher in patients with cancer (p=0.02). Among patients who underwent R0 resection, those with early recurrence had a significantly higher pre-/post-operative Tr1 ratio (p<0.05). Median pre-/post-operative ratios of Foxp3Tregs and Tr1s predicted early recurrence with 85.6% sensitivity and 93.3% specificity. Disease-free survival was significantly lower in patients with high IL-10 expression in resected specimens. CONCLUSION: Peripheral Tregs and Tr1 indicate immunological state against cancer. Copyright
Authors: Robyn D Gartrell; Thomas Enzler; Pan S Kim; Benjamin T Fullerton; Ladan Fazlollahi; Andrew X Chen; Hanna E Minns; Subha Perni; Stuart P Weisberg; Emanuelle M Rizk; Samuel Wang; Eun Jeong Oh; Xinzheng V Guo; Codruta Chiuzan; Gulam A Manji; Susan E Bates; John Chabot; Beth Schrope; Michael Kluger; Jean Emond; Raul Rabadán; Donna Farber; Helen E Remotti; David P Horowitz; Yvonne M Saenger Journal: Oncoimmunology Date: 2022-05-05 Impact factor: 7.723